Effects of COVID-19 Convalescent Plasma (CCP) on Coronavirus-associated Complications in Hospitalized Patients

  • STATUS
    Recruiting
  • participants needed
    30
  • sponsor
    Priscilla Hsue, MD
Updated on 19 February 2024
covid-19
SARS
chest imaging
respiratory symptom
coronavirus infection
acute respiratory syndrome (sars)

Summary

The purpose of this study assess the efficacy and safety of anti-SARS-CoV-2 convalescent plasma in hospitalized patients with acute respiratory symptoms up to 14 days after the onset of initial symptoms.

Description

A total of 30 eligible subjects will be randomized in a 1:1 ratio to receive either convalescent fresh frozen plasma (frozen within 8 hours of collection) of PF24 (frozen within 24 hours) from blood donors who have recovered from COVID-19 containing antibodies to SARS-CoV-2 or control (standard fresh frozen plasma collected prior to 12/1/2019 or with documented negative SARS-CoV-2 antibody). Should additional anti-COVID agents (anti-viral and/or anti-inflammatory) become available for use as standard of care during implementation, the sample size will be recalculated and increased to account for the estimated impact that these agents may have on the reducing the progression to the primary endpoint of severe hypoxemia.

Details
Condition Covid 19, Sars-CoV2
Age 18-100 years
Treatment Placebo, COVID-19 Convalescent Plasma (CCP)
Clinical Study IdentifierNCT04421404
SponsorPriscilla Hsue, MD
Last Modified on19 February 2024

Eligibility

Yes No Not Sure

Inclusion Criteria

Patients 18 years of age
Hospitalized with COVID-19
Enrolled within 72 hours of hospitalization OR within day 14 from first signs of illness
Pulmonary infiltrates on chest imaging
Oxygenation of <95% on room air
Laboratory confirmed COVID-19

Exclusion Criteria

Contraindication to transfusion due to inability to tolerate additional fluid, such as due to decompensated congestive heart failure
Baseline requirement for oxygen supplementation prior to COVID-19 infection or use of positive pressure therapy for sleep disordered breathing
Currently experiencing severe hypoxemic failure, as defined in study endpoints
Prior receipt of plasma products, IVIG, or hyperimmune globulin within past 3 months
Not currently enrolled another interventional clinical trial of COVID-19 treatment
Note: If taking medications with potential anti-COVID activity that do not yet
have data to support efficacy, such as hydroxychloroquine, these medications
must be stopped prior to enrollment. Receipt of current standard of care
COVID-19 treatment, including remdesivir is permitted and should be recorded
as a concomitant medication
Note: Pregnancy is not exclusionary but will merit additional discussion of
risks & benefits in the context of ongoing pregnancy
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.